GlassScriptPhysician profile
Tameka D Byrd
NPI 1194066035
$3,682.88
in general payments reported to CMS, 2019-2025
32 companies · $973 in 2025
The $973 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $794 · 2021: $177 · 2022: $187 · 2023: $245 · 2024: $643 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $522.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $344.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $324.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $300.50 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $281.85 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.22 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $116.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $82.39 | 2020-2021 | |
| Dexcom, INC. | $80.52 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $78.12 | 2024-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.05 | 2019-2020 | |
| Inspire Medical Systems, INC. | $57.63 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $45.66 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $44.54 | 2023 | Gvoke Hypopen |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $44.03 | 2025 | The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $42.27 | 2020 | |
| Abbott Laboratories | $37.47 | 2022-2023 | Freestyle Libre 3 |
| Abbvie INC. | $35.58 | 2019-2020 | |
| Dynavax Technologies Corporation | $28.85 | 2024 | Heplisav-B |
| Avanir Pharmaceuticals, INC. | $28.69 | 2019-2020 | |
| Allergan, INC. | $26.51 | 2019-2020 | |
| Insulet Corporation | $25.43 | 2024 | Omnipod |
| Amarin Pharma, INC. | $24.98 | 2019 | |
| Astellas Pharma US INC | $22.15 | 2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $20.87 | 2019 | |
| Medtronic, INC. | $19.51 | 2023 | Abre |
| Novartis Pharmaceuticals Corporation | $18.62 | 2025 | |
| Ironwood Pharmaceuticals, INC | $16.22 | 2019 | |
| Hikma Pharmaceuticals USA | $14.74 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tameka Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.